Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Phase II Study of Velcade in Waldenstrom's Macroglobulinemia
Sponsor: Beth Israel Deaconess Medical Center
A PHASE2 clinical study on Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 5 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Millennium Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .